The Drill Down Ep. 112: TransMedics with Changebridge Capital CIO Ross Klein, Resources Connection, Kellogg, Lamb Weston Holdings, United Airlines
Oct 7, 2021
Ross Klein, Chief Investment Officer at Changebridge Capital, explains TransMedics' organ-care device and market potential. He outlines FDA approvals, how perfusion replaces ice, and the system’s impact on transplant volumes. The conversation also touches on commercialization hurdles, market size and hospital economics.
AI Snips
Chapters
Transcript
Episode notes
Perfusion Replaces Ice To Quadruple Organ Supply
- TransMedics replaces ice-box organ transport with a perfusion-based Organ Care System that keeps organs functioning and extends usable time.
- Ross Klein says this raises transplant-eligible organs from ~25% to ~85%, expanding the addressable market up to 4x.
Keeping Organs Pumping Improves Outcomes And Cuts Costs
- TransMedics' device pumps nutrient fluids through organs to keep them viable longer, improving post-surgery outcomes and lowering complication rates.
- Klein highlights potential hospital savings and higher-margin transplant volumes as commercial incentives.
ChangeBridge Owns TransMedics In Multiple Funds
- ChangeBridge owns TransMedics in both its long-short and sustainable equity ETFs because of conviction in the technology and market.
- Klein cites fund-level conviction and points listeners to changebridgefunds.com for holdings disclosure.